Drugs / LP-108
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05641259 | Feb 2023 → Dec 2024 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Guangzhou Lupeng Pharmaceutical Company LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04139434 | Jul 2020 → Dec 2025 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia | Newave Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 1 | NCT04356846 | May 2020 → Dec 2023 | chronic lymphocytic leukemia/small lymphocytic lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04139434 ↗ |
| Action | Inhibit | “the Oral BCL-2 Inhibitor LP-108” NCT04356846 ↗ |
| Route | Oral | “receive sequentially higher oral doses of LP-108” NCT04139434 ↗ |
| Target | BCL2 | “LP-108, a BCL-2 inhibitor” NCT05641259 ↗ |